PRODUCT
PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics
PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation
DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions
DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.
Solbinsiran Demonstrates Significant Lipid Reductions in Phase 2 Trial for Mixed Dyslipidemia
Solbinsiran, siRNA, mixed dyslipidemia, Eli Lilly, PROLONG-ANG3, apolipoprotein B, LDL-C, triglycerides
Beyond Black Box: How Data-Driven AI Is Transforming RNA Medicine Development
Aortic Valve Insufficiency, development aspects, RNA medicine, black box, Data-Driven AI, Transforming RNA Medicine Development, datasets, Drug Design, Clinical Trials
Kaken Secures Japanese Rights for Alumis’ Novel TYK2 Inhibitor ESK-001
Alumis, Kaken Pharmaceutical, ESK-001, TYK2 inhibitor, dermatology, licensing agreement, Japan
Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking the big next step after AlphaFold 3
Neo-1, Study models, molecular glues
ReSync Bio, Sapio Sciences adopt Nvidia BioNeMo to supercharge AI drug discovery
Drug Discovery, Aortic Valve Insufficiency, Sapio, Sapio Sciences, Bio, NVIDIA ‘s, BioNeMo, microservices
Servier Acquires Rights to Black Diamond’s Solid Tumor Drug BDTX-4933 in $780M Deal
Servier, Black Diamond Therapeutics, BDTX-4933, solid tumors, licensing agreement, RAS/RAF inhibitor
Curevo Secures $110M for Advanced Shingles Vaccine Development
Curevo Vaccine, amezosvatein, shingles vaccine, Series B funding, improved tolerability, Shingrix competitor
Pliant and Acelyrin Adopt Poison Pill Defenses Against Potential Concentra Buyout
Poison pill, Concentra Biosciences, Tang Capital Partners, Acelyrin, Pliant Therapeutics, hostile takeover defense